Read by QxMD icon Read

antidepressant and hormone therapy interactions

Mark J Millan, Jean-Michel Rivet, Alain Gobert
The highly-interconnected and neurochemically-rich frontal cortex plays a crucial role in the regulation of mood and cognition, domains disrupted in depression and other central nervous system disorders, and it is an important site of action for their therapeutic control. For improving our understanding of the function and dysfunction of the frontal cortex, and for identifying improved treatments, quantification of extracellular pools of neuromodulators by microdialysis in freely-moving rodents has proven indispensable...
October 17, 2016: Journal of Psychopharmacology
Birgit M Dietz, Atieh Hajirahimkhan, Tareisha L Dunlap, Judy L Bolton
Botanical dietary supplements are increasingly popular for women's health, particularly for older women. The specific botanicals women take vary as a function of age. Younger women will use botanicals for urinary tract infections, especially Vaccinium macrocarpon (cranberry), where there is evidence for efficacy. Botanical dietary supplements for premenstrual syndrome (PMS) are less commonly used, and rigorous clinical trials have not been done. Some examples include Vitex agnus-castus (chasteberry), Angelica sinensis (dong quai), Viburnum opulus/prunifolium (cramp bark and black haw), and Zingiber officinale (ginger)...
October 2016: Pharmacological Reviews
Sarah M Corey, Elissa Epel, Michael Schembri, Sarah B Pawlowsky, Roger J Cole, Maria Rosario G Araneta, Elizabeth Barrett-Connor, Alka M Kanaya
PURPOSE: Chronic stimulation and dysregulation of the neuroendocrine system by stress may cause metabolic abnormalities. We estimated how much cortisol and psychosocial outcomes improved with a restorative yoga (relaxation) versus a low impact stretching intervention for individuals with the metabolic syndrome. METHODS: We conducted a 1-year multi-center randomized controlled trial (6-month intervention and 6-month maintenance phase) of restorative yoga vs. stretching...
November 2014: Psychoneuroendocrinology
Caroline Antoine, Lieveke Ameye, Marianne Paesmans, Serge Rozenberg
INTRODUCTION: Women affected by breast cancer (BC) will often go through menopause at an earlier age and display more frequent and severe symptoms than women who have a natural menopause. The safety of hormone replacement therapy (HRT) and vaginal estrogens for BC survivors has been debated over time and remains unclear. Non hormonal therapies such as antidepressants, gabapentine and clonidine may be useful for those patients but there are few data about their safety. AIM: This retrospective study analyses the use by BC patients of treatments known to alleviate climacteric symptoms...
July 2014: Maturitas
Claudio N Soares
OBJECTIVE: Menopausal transition and early postmenopausal years have been described as a "window of vulnerability" for the development of depressive symptoms or depression (new or recurrent) in some women. This article aims to review contributing factors to the emergence of menopause-related depression, some of the key challenges to its proper identification and management, and evidence on effective treatment strategies. METHODS: A body of evidence (animal data, epidemiologic studies, and clinical studies) was reviewed to disentangle some of the complex interactions between changes in sex hormones and reproductive function, physical health, and mood in midlife women...
February 2014: Menopause: the Journal of the North American Menopause Society
Grace Chen, Ronald Lee, Astrid-Maria Højer, Jeppe Klint Buchbjerg, Michael Serenko, Zhen Zhao
BACKGROUND AND OBJECTIVE: The identification and quantification of potential drug-drug interactions is important for avoiding or minimizing the interaction-induced adverse events associated with specific drug combinations. Clinical studies in healthy subjects were performed to evaluate potential pharmacokinetic interactions between vortioxetine (Lu AA21004) and co-administered agents, including fluconazole (cytochrome P450 [CYP] 2C9, CYP2C19 and CYP3A inhibitor), ketoconazole (CYP3A and P-glycoprotein inhibitor), rifampicin (CYP inducer), bupropion (CYP2D6 inhibitor and CYP2B6 substrate), ethinyl estradiol/levonorgestrel (CYP3A substrates) and omeprazole (CYP2C19 substrate and inhibitor)...
October 2013: Clinical Drug Investigation
M T Fallon
Cancer-related neuropathic pain is common; it can be disease related or related to the acute or chronic effects of cancer treatment. For example, chemotherapy-induced peripheral neuropathy occurs in 90% of patients receiving neurotoxic chemotherapy. Cancer treatments have become more effective; patients are living longer with cancer and there are more cancer survivors. However, side-effects (particularly neuropathy) have become more problematic. The key to management of cancer-related neuropathy is a considered assessment, remembering not to miss the opportunity of reversing the cause of the pain with appropriate oncological management...
July 2013: British Journal of Anaesthesia
Lisette Binkhorst, Ron H J Mathijssen, Myrthe P P van Herk-Sukel, Marjolein Bannink, Agnes Jager, Erik A C Wiemer, Teun van Gelder
Tamoxifen is a largely inactive pro-drug, requiring metabolism into its most important metabolite endoxifen. Since the cytochrome P450 (CYP) 2D6 enzyme is primarily involved in this metabolism, genetic polymorphisms of this enzyme, but also drug-induced CYP2D6 inhibition can result in considerably reduced endoxifen formation and as a consequence may affect the efficacy of tamoxifen treatment. Selective serotonin reuptake inhibitors (SSRIs) and selective serotonin and norepinephrine reuptake inhibitors (SNRIs) have been effectively used for the treatment of depression and hot flashes, both of which occur frequently in tamoxifen-treated women...
June 2013: Breast Cancer Research and Treatment
Guo-Lin Chen, Gregory M Miller
Serotonin (5-HT) has been long recognized to modulate the stress response, and dysfunction of 5-HT has been implicated in numerous stress disorders. Accordingly, the 5-HT system has been targeted for the treatment of stress disorders. Tryptophan hydroxylase (TPH) is the rate-limiting enzyme in 5-HT synthesis, and the recent identification of a second, neuron-specific TPH isoform (TPH2) opened up a new area of research. With a decade of extensive investigation, it is now recognized that: (1) TPH2 exhibits a highly flexible gene expression that is modulated by an increasing number of internal and external environmental factors including the biological clock, stressors, endogenous hormones, and antidepressant therapies; and (2) genetically determined TPH2 activity is linked to a growing body of stress-related neuronal correlates and behavioral traits...
May 1, 2013: Biochemical Pharmacology
Hui Liu, Paul G M Luiten, Uli L M Eisel, Mike J L Dejongste, Regien G Schoemaker
Patients experiencing an acute myocardial infarction (AMI) have a three times higher chance to develop depression. Vice versa, depressive symptoms increase the risk of cardiovascular events. The co-existence of both conditions is associated with substantially worse prognosis. Although the underlying mechanism of the interaction is largely unknown, inflammation is thought to be of pivotal importance. AMI-induced peripheral cytokines release may cause cerebral endothelial leakage and hence induces a neuroinflammatory reaction...
May 2013: Neuroscience and Biobehavioral Reviews
Kenneth R Kaufman, Dina Podolsky, Danielle Greenman, Rehman Madraswala
OBJECTIVE: To describe what we believe is the first reported case of synergistic gynecomastia during treatment of depressive and anxiety disorders when sertraline was added to a stable medication regimen including duloxetine, rosuvastatin, and amlodipine. CASE SUMMARY: A 67-year-old male with major depression, dysthymia, obsessive-compulsive disorder, social anxiety, hypertension, diabetes, and hyperlipidemia presented with new-onset gynecomastia and breast tenderness...
January 2013: Annals of Pharmacotherapy
Qian Li, Nicole R Sullivan, Carrie E McAllister, Louis D Van de Kar, Nancy A Muma
A major problem with current anti-depressant therapy is that it takes on average 6-7 weeks for remission. Since desensitization of serotonin (5-HT)1A receptor signaling contributes to the anti-depressive response, acceleration of the desensitization may reduce this delay in response to antidepressants. The purpose of the present study was to test the hypothesis that estradiol accelerates fluoxetine-induced desensitization of 5-HT1A receptor signaling in the paraventricular nucleus of the hypothalamus (PVN) of rats, via alterations in components of the 5-HT1A receptor signaling pathway...
July 2013: Psychoneuroendocrinology
M Cortiñas-Saenz, M B Alonso-Menoyo, C L Errando-Oyonarte, I Alférez-García, M A Carricondo-Martínez
Recent studies indicate that the intravenous infusion of ketamine hydrochloride (an N-methyl-D-aspartate receptor antagonist) leads to a rapid reduction in depressive symptoms. A 42 year-old woman with breast cancer and major depression resistant to medical treatment received a 90 minute intravenous infusion of 0.3 mg/kg ketamine for 5 consecutive days. A significant reduction from 22 to 13 (-41%) was observed in the symptoms assessed using the Hamilton scale, with the effect maintained for 14 days. The possible therapeutic mechanism is discussed...
February 2013: Revista Española de Anestesiología y Reanimación
Gyula Telegdy, Andrew V Schally
Antagonists of growth hormone-releasing hormone (GH-RH), such as MZ-4-71 suppress the secretion of GH. These findings suggest that GH-RH antagonists could be used for the therapy of disorders characterized by excessive GH secretion. It has been also demonstrated that MZ-4-71 displays antidepressant effects in a modified forced swimming test in mice, exerts anxiolytic effects in an elevated plus maze test, improves memory consolidation in passive avoidance learning, and corrects the impairment of memory consolidation caused by β-amyloid (25-35) in mice...
July 15, 2012: Behavioural Brain Research
P Baldinger, G Kranz, A Höflich, M Savli, P Stein, R Lanzenberger, S Kasper
Hormonal fluctuations during the perimenopausal transition lead to physical discomfort but are also frequently accompanied by mood swings, depressive symptoms, anxiety and sleeping disorders. The important role of the neurotransmitter serotonin in the pathogenesis of anxiety disorders and major depression is unquestioned, but only little is known about the influence of sex hormones on the serotonergic system. This review provides an overview of potential risk factors for the occurrence of affective disorders in the menopausal transition and discusses possible therapeutic options...
January 2013: Der Nervenarzt
P Villaseca
OBJECTIVE: Non-hormonal treatment for menopausal vasomotor symptoms (VMS) is needed in women in whom there are medical or personal concerns on the use of hormone therapy. This paper reviews conventional and phytochemical therapies available for the relief of VMS, on their mechanisms of action, their efficacy and safety concerns. METHODS: Medline was searched through Pubmed on the names of the diverse therapies analyzed, up to June 2011. The Cochrane Controlled Clinical Trials Register Database was searched for relevant trials that provided data on treatment of menopausal hot flushes...
April 2012: Climacteric: the Journal of the International Menopause Society
Jong-Min Woo, Robert D Gibbons, Ping Qin, Hirsh Komarow, Jong Bae Kim, Christine A Rogers, J John Mann, Teodor T Postolache
OBJECTIVE: To estimate the relationship between antiallergy drug prescription rates and suicide across the United States and over time. The relationship between allergy, allergens, and suicidal behavior and suggestions of a possible immune mediation led us to hypothesize that intranasal corticosteroids, known to reduce local airway production of T-helper cell type 2 cytokines, may be associated with reduced risk of suicide relative to antihistamines, which only secondarily affect cytokine production...
October 2011: Journal of Clinical Psychiatry
V I Goudochnikov
Recently we have evaluated the role of glucocorticoids (GC) and other stress hormones in the pathogeny of age-related diseases. In order to perform this evaluation, we considered the DOHaD paradigm discussing long-term effects of adverse perinatal factors. In the present work, a part of the data collected previously was used for analyzing the role of GC in aging, as well as in age-related pharmacotherapy. The data were gathered in various databases, preferably in English, during the last 25-30 years. Although some authors suggest that GC can be considered as hormones of aging, the majority of investigators are quite careful in this respect...
2011: Advances in Gerontology, Uspekhi Gerontologii
(no author information available yet)
Tamoxifen, an oestrogen antagonist, is the standard hormone treatment for breast cancer. It is extensively transformed into its active metabolites by the cytochrome P450 enzyme system, especially into endoxifen by isoenzyme CYP 2D6. Co-administration of tamoxifen with isoenzyme CYP 2D6 inhibitors reduces this metabolism. Selective serotonin reuptake inhibitor (SSRI) antidepressants inhibit isoenzyme CYP 2D6. Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. Two epidemiological studies involving about 3700 women have shown a link between the use of SSRI antidepressants and an increased frequency of breast cancer recurrence...
July 2011: Prescrire International
Gyula Telegdy, Masaru Tanaka, Andrew V Schally
The growth hormone-releasing hormone (GH-RH) antagonist MZ-4-71 has been shown to suppress secretion of GH and insulin-like growth factor-1 (IGF-1) secretion. These findings suggested that GH-RH antagonists could be used for the therapy of disorders characterized by excessive GH secretion. A number of GH-RH antagonists has been synthesized, and shown to suppress the growth of various tumors. However, little is known about the possible action of GR-RH antagonists on brain functions. In the present work, the influence of MZ-4-71 on different aspects of brain function was studied in mice, following its administration into the lateral brain ventricle...
October 10, 2011: Behavioural Brain Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"